[Comprehensive prophylaxis and treatment of hepatitis B recurrence after liver transplantation].
The outcome of liver transplantation for end-stage liver disease secondary to hepatitis B is remarkably impacted by recurrent infection and subsequent allograft failure. Pre-operational viral replication, immunosuppression degree, and disease types play an important role in hepatitis B recurrence. This article summarizes the mechanisms, the influencing factors, and clinical diagnosis for recurrence of hepatitis B following liver transplantation, and discusses multiple strategies to prevent hepatitis B recurrence. Lamivudine in combination with low-dose hepatitis B immuno-globulin currently is the most effective therapy to prevent recurrent hepatitis B virus allograft infection. It is emphasized that effective prophylaxis approaches against hepatitis B virus recurrence should be adopted before, during, and after operation. Long-term and even life-long antiviral therapy is important for a better outcome.
Shen
Zhong-Yang
ZY
Organ Transplantation Center, the First Central Hospital of Tianjin, Tianjin 300192, China.
D003131:Combined Modality Therapy; D006510:Hepatitis B Antibodies / Q000627:therapeutic use; D006515:Hepatitis B virus / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000517:prevention & control*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D016031:Liver Transplantation; D011183:Postoperative Complications / Q000517:prevention & control*; D055502:Secondary Prevention
D006510:Hepatitis B Antibodies; D007136:Immunoglobulins; D019259:Lamivudine